Table 7.

Risk of renal events in models additionally adjusted for AKI during exposure to acid-suppression therapy

OutcomeH2 Blockers (n=20,270)PPI (n=173,321)
Incident eGFR<60 ml/min per 1.73 m2Number of patients with AKI during exposure to acid-suppression therapy (%)690 (3.40)10,903 (6.29)
HR (95% CI)11.20 (1.16 to 1.24)
Incident CKDNumber of patients with AKI during exposure to acid-suppression therapy (%)710 (3.50)12,170 (7.02)
HR (95% CI)11.28 (1.22 to 1.34)
Doubling of serum creatinineNumber of patients with AKI during exposure to acid-suppression therapy (%)749 (3.70)14,620 (8.44)
HR (95% CI)11.42 (1.32 to 1.54)
>30% decline in eGFRNumber of patients with AKI during exposure to acid-suppression therapy (%)720 (3.55)11,797 (6.81)
H R (95% CI)11.28 (1.24 to 1.33)
ESRDNumber of patients with AKI during exposure to acid-suppression therapy (%)760 (3.75)16,063 (9.27)
HR (95% CI)11.79 (1.10 to 2.89)
ESRD or >50% decline in eGFRNumber of patients with AKI during exposure to acid-suppression therapy (%)748 (3.69)14,293 (8.25)
HR (95% CI)11.38 (1.29 to 1.47)
  • HRs were obtained from Cox models adjusted for AKI during exposure to acid-suppression therapy, baseline eGFR, age, race, sex, diabetes mellitus, hypertension, cardiovascular disease, peripheral artery disease, cerebrovascular disease, chronic lung disease, hepatitis C, HIV, dementia, gastroesophageal reflux disease, upper gastrointestinal tract bleeding, ulcer disease, H. pylori infection, Barrett esophagus, achalasia, stricture, and esophageal adenocarcinoma.